JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Skip to the beginning of the images gallery

Mfg Part Number

Ab03127-1.1

Vector Labs Ab03127-1.1 Anti-BCMA [CA8], Mouse IgG1, kappa (200 μg)

VECTOR LABS

Be the first to review this product

Quick Overview

The original mouse parental antibody 118G03 was generated by immunizing SJL mice with recombinant human BCMA/TNFRSF17-Fc chimera (R&D 193-Fc) by using the RIMMS method (Rapid immunization multiple sites). A chimeric version of this antibody was generated and it is called CA8.

$517.40

Order will ship within 1-3 business days

Description

Product Class: Purified
Clone ID: CA8
Synonyms: CD269; BCM; TNFRSF17; Tumor necrosis factor receptor superfamily member 17; B-cell maturation protein; S307118G03; 118G03
Amount: 200 μg
Application Codes Clone: ELISA; FC
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG1
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Specificity Statement: This antibody binds human and cynomolgus monkey BCMA and does not bind TACI or BAFF-R proteins. BCMA acts as a receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. BCMA expression is highest on terminally differentiated B cells. BCMA is involved in mediating the survival of plasma cells for maintaining long-term humoral immunity. It also activates NF-kappa-B and JNK. The expression of BCMA has been linked to a number of cancers, autoimmune disorders, and infectious diseases.
Application Notes: The binding characterization of this antibody towards human and cynomolgus monkey recombinant BCMA was done using ELISA (US9273141). The binding of the antibody to membrane bound BCMA expressed on HEK293, H929, OPM-2, JJN-3 and U266 cells was done using flow cytometry (US9273141). This antibody neutralizes binding of both BCMA ligands BAFF and APRIL, and subsequently blocks the induction of NF-κB signaling cascades (PMID: 26370838). The EC50 values for chimeric CA8 were calculated to be 0.695 μg/mL and 0.773 μg/mL respectively (US9273141). This antibody neutralized both BAFF and APRIL induced NfkappaB cell signaling in H-929 cells. This antibody was also reported to kill BCMA expressing ARH77 cells via ADCC. This antibody was also used in the generation of an antibody-drug conjugate for possible application in the treatment of multiple myeloma (US9273141).

Product Class:	Purified
Clone ID:	CA8
Synonyms:	CD269; BCM; TNFRSF17; Tumor necrosis factor receptor superfamily member 17; B-cell maturation protein; S307118G03; 118G03
Amount:	200 μg
Application Codes Clone:	ELISA; FC
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG1
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Specificity Statement:	This antibody binds human and cynomolgus monkey BCMA and does not bind TACI or BAFF-R proteins. BCMA acts as a receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. BCMA expression is highest on terminally differentiated B cells. BCMA is involved in mediating the survival of plasma cells for maintaining long-term humoral immunity. It also activates NF-kappa-B and JNK. The expression of BCMA has been linked to a number of cancers, autoimmune disorders, and infectious diseases.
Application Notes:	The binding characterization of this antibody towards human and cynomolgus monkey recombinant BCMA was done using ELISA (US9273141). The binding of the antibody to membrane bound BCMA expressed on HEK293, H929, OPM-2, JJN-3 and U266 cells was done using flow cytometry (US9273141). This antibody neutralizes binding of both BCMA ligands BAFF and APRIL, and subsequently blocks the induction of NF-κB signaling cascades (PMID: 26370838). The EC50 values for chimeric CA8 were calculated to be 0.695 μg/mL and 0.773 μg/mL respectively (US9273141). This antibody neutralized both BAFF and APRIL induced NfkappaB cell signaling in H-929 cells. This antibody was also reported to kill BCMA expressing ARH77 cells via ADCC. This antibody was also used in the generation of an antibody-drug conjugate for possible application in the treatment of multiple myeloma (US9273141).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews